RxDoctor Payments Data

Bridgette Keene

Family · Roanoke, VANPI 1659921369

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 61 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$424
  • Pfizer$315
  • Astellas Pharma US Inc$304
  • Myovant Sciences Inc.$71
  • Blue Earth Diagnostics$48
  • ABC Home Medical Supply, Inc.$32

What the payments were for

  • Food & beverage$1,12995%
  • Education$655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast22$424
Pfizer16$315
Astellas Pharma US Inc16$304
Myovant Sciences Inc.4$71
Blue Earth Diagnostics2$48
ABC Home Medical Supply, Inc.1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,194 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$53,065
Medicare patients
318
Services billed
1,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron159$105,025
OrgovyxRelugolix12$32,827
Methenamine Hippurate81$6,015
Tamsulosin Hcl358$4,060
Finasteride306$3,536
Silodosin37$3,490
Solifenacin Succinate104$3,086
Estradiol32$2,109
Alfuzosin Hcl ErAlfuzosin Hcl98$2,055
Dutasteride25$2,023
Potassium Citrate ErPotassium Citrate13$1,561
Trospium Chloride27$1,135
Oxybutynin Chloride ErOxybutynin Chloride30$793
Terazosin Hcl20$481
Cephalexin29$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$304$105,025159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →